How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,746 results for

Ages and Stages Questionnaire

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. New Single-Stage Double Osteotomy for Late-Presenting Infantile Tibia Vara: A Comprehensive Approach Full Text available with Trip Pro

types were described.This is the first study to use a single-stage double osteotomy performed proximal to the tibial tubercle for the late-presenting ITV for children 7 years of age or older. In addition to the effective correction of the 4 major tibial deformities, a lateral proximal tibial hemi-epiphysiodesis minimizes recurrence of tibia vara. A contralateral proximal tibial epiphysiodesis is recommended for treated skeletally immature patients with unilateral disease.Therapeutic level IV. See (...) New Single-Stage Double Osteotomy for Late-Presenting Infantile Tibia Vara: A Comprehensive Approach Successful surgical treatment of late-presenting infantile tibia vara (ITV) patient requires the correction of oblique deformities. The purpose of this study was to report on a new comprehensive approach to correct and prevent recurrence of these deformities with a single procedure.Medical records of 23 consecutive children (7 to 18 y) with advanced ITV (29 knees) were retrospectively reviewed

2017 Journal of pediatric orthopedics

222. First Line Therapy of Advanced Stage Follicular Lymphoma in Patients Not Eligible for Standard Immunochemotherapy

of the CIRS-G, IADL, G8 and ECOG Scores before start of treatment Histologically confirmed follicular lymphoma grade I, II or IIIa with material available for central pathology review Stage III/IV or stage II without the option of curative radiotherapy Age > 18 years No prior therapy Presence of at least one of the following symptoms or conditions requiring initiation of treatment: Bulky disease according to the GELF criteria: nodal or extranodal mass > 7cm in its greater diameter B symptoms (fever (...) First Line Therapy of Advanced Stage Follicular Lymphoma in Patients Not Eligible for Standard Immunochemotherapy First Line Therapy of Advanced Stage Follicular Lymphoma in Patients Not Eligible for Standard Immunochemotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

223. Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis

session. An sensory questionnaire and an open ended comment box will be given for participants to type in other words to describe the sensations. In dialysis patients only, blood will be drawn pre and post dialysis for serum ion concentrations. Healthy Controls Inclusion Criteria No tongue, lip, or cheek piercings Over 18 years of age Normal taste and smell function No known issues with salivation or dry mouth Willing to comply with study protocol (taste samples and provide saliva) The above protocol (...) Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2017 Clinical Trials

224. A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03357380 Recruitment Status : Active, not recruiting First Posted

2017 Clinical Trials

225. SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects

using the Patient Generated Subjective Global Assessment in patients treated with Nivolumab after SBRT for early stage NSCLC. Health-related quality of life (HRQoL) using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) in patients treated with Nivolumab after SBRT for early stage NSCLC [ Time Frame: 24 months from last dose of SBRT ] Estimation of HRQoL using the European Organization for Research and Treatment of Cancer Quality of Life (...) Questionnaire (EORTC QLQ-C30). HRQoL using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) in patients treated with Nivolumab after SBRT for early stage NSCLC. [ Time Frame: 24 months from last dose of SBRT ] Estimation of HRQoL in patients treated with Nivolumab after SBRT for early stage NSCLC using the Eurpoean Organisation for Research and Treatment of Cancer Ouality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13). Other

2017 Clinical Trials

226. Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma

characteristics and prognosis information of stage pI patients with solid subtype, micropapillary subtype, vascular involvement, pleural involvement and low differentiation. To determine the association among age, gender, smoking history, pathological subtypes, histological differentiation, pleural involvement, vascular involvement and driving mutations. Randomization: Each of the patients enrolled will be recorded in the computer system. Blank randomization will be done using a digital randomization software (...) recurrence, metastatic recurrence, or both Quality of life: assessed with Eastern Cooperative Oncology Group- quality of life questionnaire(EORTC QLQ-C30/- LC13) scale. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 300 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I

2017 Clinical Trials

227. Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC

Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03243916 Recruitment Status : Not yet

2017 Clinical Trials

228. Mindfulness-Based Blood Pressure Reduction: Stage 2a RCT

Mindfulness-Based Blood Pressure Reduction: Stage 2a RCT Mindfulness-Based Blood Pressure Reduction: Stage 2a RCT - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Mindfulness-Based Blood Pressure Reduction (...) : Stage 2a RCT (MB-BP) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03256890 Recruitment Status : Recruiting First Posted : August 22, 2017 Last Update Posted : October 31, 2017 See Sponsor: Brown University

2017 Clinical Trials

229. Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin

: From randomization until death from any cause, assessed up to 3 years ] OS will be estimated using the Kaplan-Meier method. The difference in OS between the two arms will be tested using a log-rank test. Exploratory analysis adjusting for important factors such as age, site, Zubrod performance status, and clinical stages will be conducted using Cox models. Secondary Outcome Measures : Locoregional failure (LRF) [ Time Frame: From randomization until first evidence of local, regional disease (...) for OS. Potential covariates evaluated for the multivariate models would be assigned treatment, age, Zubrod performance status, T-stage, N-stage, primary site, smoking history, other risk factors, as well as p16 and/PD-L1. Other Outcome Measures: Secondary biomarker analysis [ Time Frame: Baseline up to 1 month after last systemic dose ] Will perform multiparametric flow cytometry on peripheral mononuclear cells (PBMC) from patient-derived blood samples to quantify changes in immune cell frequency

2017 Clinical Trials

230. Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Behavioral: Exercise Intervention Other: Laboratory Biomarker Analysis Device: Monitoring Device Other: Quality-of-Life Assessment Other: Questionnaire Administration Not Applicable Detailed Description: PRIMARY OBJECTIVES: I. To determine the effects of a 4-month circuit, interval-based aerobic and resistance exercise (CARE) intervention on metabolic dysregulation. SECONDARY OBJECTIVES: I. To determine the effects (...) Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

231. A Patient Navigation Program to Increase Access to Early Supportive Care in Patients With Stage IV Solid Tumors

to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male or female patients 18 years of age and older Newly diagnosed stage IV solid tumor Recurrent stage IV solid tumor Exclusion Criteria (...) A Patient Navigation Program to Increase Access to Early Supportive Care in Patients With Stage IV Solid Tumors A Patient Navigation Program to Increase Access to Early Supportive Care in Patients With Stage IV Solid Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

232. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Histologically or cytologically confirmed extensive-stage disease small cell lung cancer (ED SCLC) at initial diagnosis with ongoing clinical benefit (stable disease [SD], partial response [PR], or complete response [CR]) following completion of 4 cycles of first-line (...) A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information

2017 Clinical Trials

233. A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) The safety and scientific validity of this study is the responsibility of the study sponsor

2017 Clinical Trials

234. Stage Ib Trial of mSMART With Varenicline

Stage Ib Trial of mSMART With Varenicline Stage Ib Trial of mSMART With Varenicline - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Stage Ib Trial of mSMART With Varenicline (mSMART-v) The safety (...) medication adherence in substance users. The study team has developed and assessed mSMART in a Stage Ia trial among 9 non-treatment seeking cigarette smokers. mSMART provides psychoeducation about medication (e.g., dosage, benefits, side-effects), assessment of medication compliance and characteristics associated with substance use, provides reminders to take medications, and conducts real-time medication event feedback intervention. The aim of the current study is to extend findings from the Stage Ia

2017 Clinical Trials

235. Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Stage 0-III Melanoma

for SSE and sun protection behaviors, perceived benefits of SSE and sun protection behaviors, perceived barriers to SSE and sun protection behaviors, and perceived controllability of melanoma. TERTIARY OBJECTIVES: I. To examine moderators of the impact of the intervention. To evaluate whether ITW effects are moderated by the following factors: time since diagnosis, disease stage, age, sex, income, education, Internet experience, distress about melanoma, worry about recurrence, and evaluation and usage (...) to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Phase I: Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma Phase I: From 3-36 months post-surgical treatment Phase I

2017 Clinical Trials

236. Personalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors

Personalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors Personalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Personalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2017 Clinical Trials

237. Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

, resectable breast cancer (Stage 0, I, II, or III) prior to age 50, and are within 5 years of diagnosis Have completed all surgery, radiation, and/or chemotherapy treatments at least 6 months previously; may still be receiving trastuzumab or endocrine adjuvant therapy Ability to complete evaluation surveys in English Have evidence of at least mild clinical depression on a standardized screening questionnaire Exclusion Criteria: Has a breast cancer recurrence, metastasis, or another interval cancer (...) education may help improve the health behaviors of younger breast cancer survivors. Condition or disease Intervention/treatment Phase Cancer Survivor Early-Stage Breast Carcinoma Stage 0 Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Other: Educational Intervention Other: Laboratory Biomarker Analysis Procedure: Meditation Therapy Other: Questionnaire Administration

2017 Clinical Trials

238. Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC-II-IV, With a 5-Fluorouracil-based Standard Radiochemotherapy Followed by Total Mesorectal Excisi

Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC-II-IV, With a 5-Fluorouracil-based Standard Radiochemotherapy Followed by Total Mesorectal Excisi Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC-II-IV, With a 5-Fluorouracil-based Standard Radiochemotherapy Followed by Total (...) Stages UICC-II-IV, With a 5-Fluorouracil-based Standard Radiochemotherapy Followed by Total Mesorectal Excision. (TransValid-A) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03034473 Recruitment Status : Active, not recruiting First Posted : January 27, 2017 Last Update Posted : October 16, 2018

2017 Clinical Trials

239. Taste And Smell TEsting in End Stage Renal Disease

. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Adults (aged 18 or older) who have end-stage (...) renal disease requiring chronic dialysis. Criteria Inclusion Criteria: Aged 18 or older End-stage renal disease requiring chronic dialysis Exclusion Criteria: Known allergy to quinine Presence of a pacemaker or internal defibrillator Pregnancy or breastfeeding Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2017 Clinical Trials

240. Palliative Gastric Resection Plus Chemotherapy Versus Chemotherapy Alone in Stage IV Gastric Cancer

Palliative Gastric Resection Plus Chemotherapy Versus Chemotherapy Alone in Stage IV Gastric Cancer Palliative Gastric Resection Plus Chemotherapy Versus Chemotherapy Alone in Stage IV Gastric Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Palliative Gastric Resection Plus Chemotherapy Versus Chemotherapy Alone in Stage IV Gastric Cancer (SURGIGAST) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03042169

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>